Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 133 PK and Safety in Renal Impairment
NCT07429045Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of maridebart cafraglutide in obesity (5 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Concentration at Day 120, Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration at Day 120 and 1 more. Started Mar 2025; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07429045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429045.